Becton Dickinson (BDX) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 4, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Thomas E. Polen Jr., CEO, President sold 2,993 shares at $210.00 ($629K).
- Trade date
- Nov 5, 2026
- Disclosed to the SEC
- Nov 9, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All BDX insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
BDX insider transactions (Form 4)
Open-market purchases and sales. 58 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 9SEC | Thomas E. Polen Jr.CEO, President | Sell Plan | 2,993110,163 held (−3%) | $210.00 | $629K | +2.0% | — |
| Oct 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7619,568 held (−0%) | $198.13 | $15K | +8.2% | — |
| Sep 29SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7619,644 held (−0%) | $183.70 | $14K | +16.6% | — |
| Aug 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 16519,720 held (−1%) | $188.49 | $31K | +13.7% | — |
| Aug 14SEC | Thomas E. Polen Jr.CEO, President | Sell Plan | 4,152110,163 held (−4%) | $185.00 | $768K | +15.8% | — |
| Aug 12SEC | Roland GoettePresident | Sell | 2,43814,856 held (−14%) | $180.84 | $441K | +18.5% | — |
| Jul 28SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7520,934 held (−0%) | $157.13 | $12K | +36.4% | — |
| Jun 26SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7521,009 held (−0%) | $152.80 | $11K | +40.2% | — |
| Jun 25SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,10013,172 held (−8%) | $145.66 | $160K | +47.1% | — |
| Jun 11SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,10014,272 held (−7%) | $151.48 | $167K | +41.5% | — |
| Jun 3SEC | Thomas E. Polen Jr.CEO, President | Sell Plan | 2,764110,163 held (−2%) | $146.35 | $405K | +46.4% | — |
| May 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7521,084 held (−0%) | $147.35 | $11K | +45.4% | — |
| Apr 28SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7421,159 held (−0%) | $151.94 | $11K | +41.0% | — |
| Mar 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7521,233 held (−0%) | $156.83 | $12K | +36.6% | — |
| Feb 27SEC | Michael FeldEvp, Chief Revenue Officer | Sell Plan | 7521,308 held (−0%) | $181.84 | $14K | +17.8% | — |
| Feb 18SEC | Bertram L. ScottDirector | Sell | 95336,763 held (−3%) | $182.61 | $174K | +17.3% | — |
| Jan 28SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 7516,431 held (−0%) | $202.73 | $15K | +5.7% | — |
| Jan 16SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 1,01012,095 held (−8%) | $206.54 | $209K | +3.7% | — |
| Jan 16SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 60013,105 held (−4%) | $209.00 | $125K | +2.5% | — |
| Dec 29SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 7416,506 held (−0%) | $196.08 | $15K | +9.3% | — |
| Dec 17SEC | Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | Sell Plan | 62913,105 held (−5%) | $196.03 | $123K | +9.3% | — |
| Dec 2SEC | Michael FeldEvp, Cro & Pres. Life Sciences | Sell Plan | 7516,580 held (−0%) | $193.36 | $15K | +10.8% | — |
| Nov 7SEC | Bertram L. ScottDirector | Sell | 21735,816 held (−1%) | $176.58 | $38K | +21.4% | — |
| Oct 28SEC | Michael FeldPresident | Sell Plan | 578,245 held (−1%) | $186.01 | $11K | +15.2% | — |
Similar past setups: not applicable. BDX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with BDX in the Research Lab
BDX has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Becton Dickinson insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $3.4M of BDX stock on the open market; P/E 41.3 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
BDX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $644K | 2 |
| Q3 2026 | — | 0 | $1.3M | 5 |
| Q2 2026 | — | 0 | $765K | 6 |
| Q1 2026 | — | 0 | $549K | 6 |
| Q4 2025 | — | 0 | $201K | 5 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Becton Dickinson insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $3.4M. 21 of 24 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
BDX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 5, 2026 | +7.9% | Sold $15K | +1.3%S&P -4.1% | pending |
| Aug 6, 2026 | +10.9% | Sold $12K | +3.6%S&P +0.5% | +4.5% |
| May 7, 2026 | -7.6% | Sold $11K | +3.2%S&P +0.5% | +1.2% |
| Apr 2, 2026 | -3.3% | Sold $12K | -0.7%S&P +0.6% | -6.8% |
| Feb 9, 2026 | +1.9% | Sold $349K | +4.0%S&P +0.2% | -6.4% |
| Nov 6, 2025 | -6.7% | Sold $11K | +0.8%S&P -1.0% | +9.1% |
| Oct 15, 2025 | +2.4% | None | -1.6%S&P -0.2% | +4.2% |
| Aug 7, 2025 | -4.9% | None | +12.2%S&P +0.7% | -0.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
BDX short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded BDX
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +40.5% |
Insiders at Becton Dickinson
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Thomas E. Polen Jr.CEO, President | — | $1.8M | Nov 9, 2026 | — | — |
| Michael David GarrisonEvp & Pres Med.Essntl&Biopharm | — | $784K | Jun 25, 2026 | — | — |
| Roland GoettePresident | — | $441K | Aug 12, 2026 | — | — |
| Bertram L. ScottDirector | — | $212K | Feb 18, 2026 | — | — |
| Michael FeldEvp, Chief Revenue Officer | — | $186K | Oct 27, 2026 | — | — |
| Vitor RoqueCFO | — | — | Sep 3, 2026 | — | — |
| Bilal MuhsinPresident | — | — | Jul 6, 2026 | — | — |
| Peter MenziusoPresident | — | — | Jun 2, 2026 | — | — |
| Shana Carol NealEvp And Chief People Officer | — | — | Apr 6, 2026 | — | — |
| Lanesha MinnixGeneral Counsel | — | — | Mar 17, 2026 | — | — |
| Pamela L. SpiknerSvp Controller & Cao | — | — | Mar 4, 2026 | — | — |
| Jacqueline WrightDirector | — | — | Jan 29, 2026 | — | — |
| Joanne WaldstreicherDirector | — | — | Jan 29, 2026 | — | — |
| Timothy M. RingDirector | — | — | Jan 29, 2026 | — | — |
| Christopher Ian Montague JonesDirector | — | — | Jan 29, 2026 | — | — |
| Robert Luther HuffinesDirector | — | — | Jan 29, 2026 | — | — |
| William M. BrownDirector | — | — | Jan 29, 2026 | — | — |
| Gregory HayesDirector | — | — | Jan 29, 2026 | 0 of 1 | — |
| Carrie L. ByingtonDirector | — | — | Jan 29, 2026 | — | — |
| R. Andrew EckertDirector | — | — | Jan 29, 2026 | — | — |
| Jeffrey William HendersonDirector | — | — | Jan 29, 2026 | 0 of 1 | — |
| David ShanEvp And Chief Isc Officer | — | — | Jan 6, 2026 | — | — |
| Richard ByrdPresident | — | — | Dec 1, 2025 | — | — |
| Christopher DeloreficeCFO | — | — | Dec 1, 2025 | — | — |
| Pavan Kumar MocherlaPresident | — | — | Dec 1, 2025 | — | — |
Board links: companies that share insiders with BDX
Directors and executives who filed Form 4s for BDX and another company in the last 12 months.
- AEISAdvanced Energy Industries Lanesha Minnix General Counsel here · Director at AEIS · latest filing Nov 17, 2026
- DGXQuest Diagnostics Timothy M. Ring Director here · Director at DGX · latest filing May 21, 2026
- EQHEquitable Holdings Bertram L. Scott Director here · Director at EQH · latest filing Sep 21, 2026
- MMM3M William M. Brown Director here · CEO, Chair at MMM · latest filing May 4, 2026
- PODDInsulet Robert Luther Huffines Director here · Director at PODD · latest filing Oct 2, 2026
- PSXPhillips 66 Gregory Hayes Director here · Director at PSX · latest filing Jan 29, 2026
- QCOMQualcomm Jeffrey William Henderson Director here · Director at QCOM · latest filing Mar 18, 2026
- RMDResMed Christopher Delorefice CFO here · Director at RMD · latest filing Dec 1, 2025
- ULTAUlta Beauty Christopher Delorefice CFO here · CFO at ULTA · latest filing Apr 2, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
BDX stock: common questions
Are Becton Dickinson insiders buying BDX stock?
No. No Becton Dickinson insider reported an open-market purchase of BDX in the past 12 months.
Are Becton Dickinson insiders selling BDX stock?
5 insiders reported sales worth $3.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BDX's P/E ratio?
BDX trades at about 41.3 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is BDX's 52-week range?
Over the past year BDX has traded between $139.89 and $218.03. It last closed at $214.28 on Nov 20, 2026.